Share Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

Business Wire · INCY · November 16, 2026

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: Business Wire ↗